<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MSJ</journal-id>
<journal-id journal-id-type="hwp">spmsj</journal-id>
<journal-id journal-id-type="nlm-ta">Mult Scler</journal-id>
<journal-title>Multiple Sclerosis Journal</journal-title>
<issn pub-type="ppub">1352-4585</issn>
<issn pub-type="epub">1477-0970</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1352458512454345</article-id>
<article-id pub-id-type="publisher-id">10.1177_1352458512454345</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Glutamate gene polymorphisms predict brain volumes in multiple sclerosis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Strijbis</surname><given-names>Eva MM</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512454345">1</xref>
<xref ref-type="aff" rid="aff2-1352458512454345">2</xref>
<xref ref-type="fn" rid="fn1-1352458512454345">*</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Inkster</surname><given-names>Becky</given-names></name>
<xref ref-type="aff" rid="aff3-1352458512454345">3</xref>
<xref ref-type="aff" rid="aff4-1352458512454345">4</xref>
<xref ref-type="fn" rid="fn1-1352458512454345">*</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Vounou</surname><given-names>Maria</given-names></name>
<xref ref-type="aff" rid="aff3-1352458512454345">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Naegelin</surname><given-names>Yvonne</given-names></name>
<xref ref-type="aff" rid="aff5-1352458512454345">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kappos</surname><given-names>Ludwig</given-names></name>
<xref ref-type="aff" rid="aff5-1352458512454345">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Radue</surname><given-names>Ernst-Wilhelm</given-names></name>
<xref ref-type="aff" rid="aff5-1352458512454345">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Matthews</surname><given-names>Paul M</given-names></name>
<xref ref-type="aff" rid="aff4-1352458512454345">4</xref>
<xref ref-type="aff" rid="aff6-1352458512454345">6</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Uitdehaag</surname><given-names>Bernard MJ</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512454345">1</xref>
<xref ref-type="aff" rid="aff7-1352458512454345">7</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Barkhof</surname><given-names>Frederik</given-names></name>
<xref ref-type="aff" rid="aff8-1352458512454345">8</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Polman</surname><given-names>Chris H</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512454345">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Montana</surname><given-names>Giovanni</given-names></name>
<xref ref-type="aff" rid="aff3-1352458512454345">3</xref>
<xref ref-type="fn" rid="fn1-1352458512454345">*</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Geurts</surname><given-names>Jeroen JG</given-names></name>
<xref ref-type="aff" rid="aff2-1352458512454345">2</xref>
<xref ref-type="fn" rid="fn1-1352458512454345">*</xref>
</contrib>
</contrib-group>
<aff id="aff1-1352458512454345"><label>1</label>Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands</aff>
<aff id="aff2-1352458512454345"><label>2</label>Department of Anatomy and Neuroscience, Section of Clinical Neuroscience, VU University Medical Centre, Amsterdam, The Netherlands</aff>
<aff id="aff3-1352458512454345"><label>3</label>Department of Mathematics, Statistics Section, Imperial College London, UK</aff>
<aff id="aff4-1352458512454345"><label>4</label>Centre for Neuroscience, Department of Medicine, Hammersmith Hospital, Imperial College London, UK</aff>
<aff id="aff5-1352458512454345"><label>5</label>Department of Neurology and Medical Image Analysis Centre, University Hospital, Basel, Switzerland</aff>
<aff id="aff6-1352458512454345"><label>6</label>GlaxoSmithKline Clinical Imaging Centre, Hammersmith Hospital, London, UK</aff>
<aff id="aff7-1352458512454345"><label>7</label>Department of Epidemiology and Biostatistics, VU University Medical Centre, Amsterdam, The Netherlands</aff>
<aff id="aff8-1352458512454345"><label>8</label>Department of Radiology, VU University Medical Centre, Amsterdam, The Netherlands</aff>
<author-notes>
<fn fn-type="other" id="fn1-1352458512454345">
<label>*</label>
<p>These authors contributed equally.</p>
</fn>
<corresp id="corresp1-1352458512454345">EMM Strijbis, VU University Medical Centre, Departments of Neurology and Anatomy and Neuroscience, Section of Clinical Neurosciences, De Boelelaan 1117, PO Box 7057, 1007 MB Amsterdam, The Netherlands. Email: <email>e.strijbis@vumc.nl</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2013</year>
</pub-date>
<volume>19</volume>
<issue>3</issue>
<fpage>281</fpage>
<lpage>288</lpage>
<history>
<date date-type="received">
<day>6</day>
<month>2</month>
<year>2012</year>
</date>
<date date-type="rev-recd">
<day>24</day>
<month>4</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>10</day>
<month>6</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="section1-1352458512454345">
<title>Background:</title>
<p>Several genetic markers have been associated with multiple sclerosis (MS) susceptibility; however, uncovering the genetic aetiology of the complex phenotypic expression of MS has been more difficult so far. The most common approach in imaging genetics is based on mass-univariate linear modelling (MULM), which faces several limitations.</p>
</sec>
<sec id="section2-1352458512454345">
<title>Objective:</title>
<p>Here we apply a novel multivariate statistical model, sparse reduced-rank regression (sRRR), to identify possible associations of glutamate related single nucleotide polymorphisms (SNPs) and multiple MRI-derived phenotypes in MS.</p>
</sec>
<sec id="section3-1352458512454345">
<title>Methods:</title>
<p>Seven phenotypes related to brain and lesion volumes for a total number of 326 relapsing–remitting and secondary-progressive MS patients and a total of 3809 glutamate related and control SNPs were analysed with sRRR, which resulted in a ranking of SNPs in decreasing order of importance (‘selection probability’). Lasso regression and MULM were used as comparative statistical techniques to assess consistency of the most important associations over different statistical models.</p>
</sec>
<sec id="section4-1352458512454345">
<title>Results:</title>
<p>Five SNPs within the NMDA-receptor-2A-subunit (GRIN2A) domain were identified by sRRR in association with normalized brain volume (NBV), normalized grey matter volume and normalized white matter volume (NMWM). The association between GRIN2A and both NBV and NWMV was confirmed in MULM and Lasso analysis.</p>
</sec>
<sec id="section5-1352458512454345">
<title>Conclusions:</title>
<p>Using a novel, multivariate regression model confirmed by two other statistical approaches we show associations between GRIN2A SNPs and phenotypic variation in NBV and NWMV in this first exploratory study. Replications in independent datasets are now necessary to validate these findings.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Multiple sclerosis</kwd>
<kwd>genetics</kwd>
<kwd>MRI</kwd>
<kwd>single nucleotide polymorphisms</kwd>
<kwd>glutamate</kwd>
<kwd>endophenotyping</kwd>
<kwd>atrophy</kwd>
<kwd>white matter</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section6-1352458512454345" sec-type="intro">
<title>Introduction</title>
<p>Multiple sclerosis (MS) is a complex disease characterized by a substantial pathological heterogeneity and highly variable clinical course. In recent years, large genome-wide association studies (GWAS) have identified several loci that influence MS susceptibility.<sup><xref ref-type="bibr" rid="bibr1-1352458512454345">1</xref><xref ref-type="bibr" rid="bibr2-1352458512454345"/>-<xref ref-type="bibr" rid="bibr3-1352458512454345">3</xref></sup> However, the extent to which the heterogenic nature of MS phenotype expression can be explained by genetic factors remains insufficiently understood.</p>
<p>In contrast to susceptibility studies, phenotypic data is often multi-dimensional and a number of statistical challenges arise when conventional statistical models like mass-univariate linear modelling (MULM) are used for genotype-phenotype studies.<sup><xref ref-type="bibr" rid="bibr4-1352458512454345">4</xref><xref ref-type="bibr" rid="bibr5-1352458512454345"/>–<xref ref-type="bibr" rid="bibr6-1352458512454345">6</xref></sup> Recently a novel multivariate, penalized regression approach, sparse reduced-rank regression (sRRR), has been introduced that overcomes these difficulties.<sup><xref ref-type="bibr" rid="bibr7-1352458512454345">7</xref></sup> sRRR offers a way of simultaneously searching for multiple markers that are highly predictive of a combination of phenotypes, thus taking into account the multivariate nature of the data. Moreover, by framing the identification of genetic associations as a variable selection problem, rather than one of hypothesis testing, there is no need to rely on multiple testing correction procedures.</p>
<p>This exploratory study applies this novel sRRR model, as well as two further comparative models, the Lasso regression model and the MULM approach, in an attempt to elucidate the genetic variability of MS-related neuroimaging phenotypes. Given the body of evidence that glutamate biology is implicated in both neurodegenerative and neuroinflammatory processes<sup><xref ref-type="bibr" rid="bibr8-1352458512454345">8</xref><xref ref-type="bibr" rid="bibr9-1352458512454345"/>–<xref ref-type="bibr" rid="bibr10-1352458512454345">10</xref></sup>, we here examined single nucleotide polymorphisms (SNPs) involved in glutamate metabolism, in association with neuroimaging phenotypes that capture neuroinflammation and neurodegeneration in MS.</p>
</sec>
<sec id="section7-1352458512454345" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="section8-1352458512454345">
<title>Cases</title>
<p>Patients were recruited from two specialized referral centres participating in the GeneMSA consortium:<sup><xref ref-type="bibr" rid="bibr3-1352458512454345">3</xref></sup> the University Hospital in Basel and the VU University Medical Centre in Amsterdam. All included patients had a diagnosis of either relapsing–remitting MS (RRMS) or secondary-progressive MS (SPMS).<sup><xref ref-type="bibr" rid="bibr11-1352458512454345">11</xref></sup> In all included subjects, disability was assessed with the Expanded Disability Status Scale (EDSS) at baseline.<sup><xref ref-type="bibr" rid="bibr12-1352458512454345">12</xref></sup> The study protocol was approved by the institutional ethics review boards of the clinical centres and all patients gave written informed consent prior to participation.</p>
</sec>
<sec id="section9-1352458512454345">
<title>Image acquisition</title>
<p>MR-imaging was performed on two 1.5T MR-systems (Amsterdam: Siemens Vision; Basel: Siemens Avanto) at baseline and after one year. Dual echo proton density (PD)-T2-weighted images (<italic>TR</italic>: 2000–4000 ms; <italic>TE</italic>: 14–20/80–108 ms) with interleaved axial 3.0 mm-thick slices and an in-plane resolution of 1.0 × 1.0 mm<sup>2</sup> were acquired. Additionally, post-contrast T1-weighted spin-echo images (<italic>TR</italic>: 467–650 ms; <italic>TE</italic>: 8–17ms; axial 3.0 mm-thick slices with an in-plane resolution of 1.0 × 1.0 mm<sup>2</sup>) were obtained. For brain volume measurements, 3D-T1 images were acquired (<italic>TR</italic>: 7–20.8 ms; <italic>TE</italic>: 2–4 ms; <italic>TI</italic>: 300–400 ms) consisting of isotropic 1 × 1 × 1 mm<sup>3</sup> voxels.</p>
</sec>
<sec id="section10-1352458512454345">
<title>MRI phenotypes and measurements</title>
<p>Marking and measurement of focal white matter lesions was performed at the University Hospital Basel using commercial semi-automatic software (AMIRA 3.1.1; Mercury Computer Systems Inc.). T2-hyperintense lesions and T1-hypointense lesions were manually outlined on PD-images. Subsequently, baseline T1 and T2 lesion load changes after one year (T1LL-change and T2LL-change respectively) in millilitres (ml) were calculated. The T1/T2-ratio was calculated as a ratio of T1 lesion load and T2 lesion load by dividing T1LL-baseline by T2LL-baseline.</p>
<p>Brain volume analyses were performed at the Imaging Analysis Centre Amsterdam. Normalized brain volume (NBV), normalized grey matter volume (NGMV), normalized white matter (NWMV) (all in ml) and percentage brain volume change after one year (PBVC) were estimated using SIENA(X) (version 2.2) from the FMRIB software library.<sup><xref ref-type="bibr" rid="bibr13-1352458512454345">13</xref></sup> SIENA(X) registers each individual scan to MNI-152 standard space, using the skull as a scaling constraint. The volumetric scaling factor is then used to correct grey matter (GM) and white matter (WM) volumes obtained from the automated tissue segmentation to volumes normalized for head size. Scans of all subjects and the resulting segmentation maps were visually inspected for scan quality and segmentation quality, respectively.</p>
</sec>
<sec id="section11-1352458512454345">
<title>Genotyping and gene selection</title>
<p>Genotyping was performed using the Sentrix HumanHap 550 Beadchip available from Illumina. Two separate groups of SNPs were selected for analysis from the entire set of SNPs. The first group consisted of SNPs in 34 genes involved in glutamatergic neurotransmission (Supplementary Table 1). For the second group, in order to determine an adequate set of ‘control’-SNPs to be included in the study, we performed a genome-wide linear regression analysis using the linear regression option in PLINK.<sup><xref ref-type="bibr" rid="bibr14-1352458512454345">14</xref></sup> Age and disease duration were used as covariates and NBV was used as response in the regression model. The SNPs for which no association was statistically significant, that is those with the highest <italic>p</italic>-values, were selected to be included for final analysis together with the glutamate genes. HLA-DRB1*1501 rs3135388 was subsequently added in the ‘control’-group given prior evidence of a modest association of HLA-DRB1*1501 and T2LL.<sup><xref ref-type="bibr" rid="bibr15-1352458512454345">15</xref></sup></p>
</sec>
<sec id="section12-1352458512454345">
<title>Genotype and phenotype quality control (QC)</title>
<p>Patients with all phenotype data and &gt;80% of genotype data available were recruited from the GeneMSA dataset. To reduce the possibility of false-positive associations due to very small groups carrying the minor allele, we chose a relatively conservative minor allele frequency (MAF) threshold of 0.1. Furthermore, genotyping QC consisted of exclusion of SNPs with one or more missing values and exclusion of SNPs with Hardy–Weinberg equilibrium (HWE) &lt;0.01. Pairwise LD-plots for the glutamate group and ‘control’ group are shown in Supplementary Figure 1(a). Genotype QC resulted in selection of 1292 SNPs from the 2023 available SNPs for the selected 34 glutamate genes and 2517 SNPs from the control genes. In total a set of 3810 SNPs was used for analysis. Phenotype correlation coefficients were calculated for every phenotype combination to assess linear dependences among phenotypes as illustrated in Supplementary Figure 1(b).</p>
</sec>
<sec id="section13-1352458512454345">
<title>Statistical methods</title>
<p>We performed an imaging genetics study using the sRRR model to identify potential genetic associations with the MRI-phenotypes. We further performed two additional studies, one using Lasso regression and one based on MULM. Since all models are based on different assumptions (this is explained in detail below and in the Supplementary Methods), associations that were found across the three approaches were considered more reliable than those that were observed in only one or two techniques.</p>
<sec id="section14-1352458512454345">
<title>MULM</title>
<p>The most commonly used approach for detecting genetic associations is based on univariate linear regressions, modelling each SNP-phenotype pair independently. Genotype–phenotype pairs are ranked in decreasing order of importance based on their <italic>p</italic>-values. An experiment-wide significance level then needs to be determined to account for the multiple comparisons. This can be decided upon by controlling an error criterion, such as the family-wise error, routine control by a Bonferroni-correction<sup><xref ref-type="bibr" rid="bibr5-1352458512454345">5</xref></sup> or the false discovery rate.<sup><xref ref-type="bibr" rid="bibr16-1352458512454345">16</xref>,<xref ref-type="bibr" rid="bibr17-1352458512454345">17</xref></sup> In the context of imaging genetics the complex dependence structure among both genetic markers and among phenotypes must be accounted for.<sup><xref ref-type="bibr" rid="bibr18-1352458512454345">18</xref>,<xref ref-type="bibr" rid="bibr19-1352458512454345">19</xref></sup></p>
</sec>
<sec id="section15-1352458512454345">
<title>Lasso regression (Lasso)</title>
<p>Lasso is a penalized regression technique that models the joint dependence of multiple genetic markers on a quantitative phenotype. The model is able to perform variable selection, identifying subsets of the genetic markers that show the greatest effect on the phenotype.<sup><xref ref-type="bibr" rid="bibr5-1352458512454345">5</xref>,<xref ref-type="bibr" rid="bibr6-1352458512454345">6</xref>,<xref ref-type="bibr" rid="bibr20-1352458512454345">20</xref></sup> In this study Lasso is combined with a resampling approach, where the model is fitted repeatedly in sub-samples extracted from the data.<sup><xref ref-type="bibr" rid="bibr6-1352458512454345">6</xref></sup> SNPs are then ranked according to their frequency of selection (selection probability), and a final set of SNPs is obtained after deciding on a threshold on the selection probabilities.</p>
</sec>
<sec id="section16-1352458512454345">
<title>sRRR</title>
<p>Even though Lasso models all the genetic markers jointly, it treats each phenotype independently of all others. However, variability in correlated phenotypes is expected to be explained by common genetic variation and accounting for the multivariate nature of the disease phenotype has the potential to further amplify the signal and eventually increase the statistical power to detect true associations.</p>
<p>sRRR is a penalized regression technique specifically designed for multivariate modelling of high-dimensional imaging-phenotypes and genetic covariates. Following extensive simulations, sRRR has been proven to provide higher statistical power compared with MULM.<sup><xref ref-type="bibr" rid="bibr7-1352458512454345">7</xref></sup> Similarly with Lasso, this model is combined with a data resampling procedure resulting in ordering of the SNPs and phenotypes based on selection probabilities. The sRRR model assumes the existence of multiple ranks, each capturing different genetic effects on the disease phenotypes. To examine subsequent ranks, data of SNPs and phenotypes with a selection probability ≥ 0.5 are regressed out prior to the subsequent rank 2 analysis. Further ranks are determined by repeating the same procedure.</p>
<p>In the current study, sRRR was used to model the joint dependence of the entire set of genetic markers and phenotypes (i.e. all seven different MRI measurements). Only the first two ranks were considered as further ranks were deemed not informative enough for the present study. Lasso was used to model the joint dependence of the entire set of genetic markers on each phenotype independently and the MULM approach was used to examine SNP-phenotype pair-wise associations. For MULM, Bonferroni-correction for multiple testing was performed by taking into account all the tests performed within the group, i.e. adjusting <italic>p</italic>-values by all <italic>p</italic>(SNPs) × 7 phenotypes, or by correcting for the per-phenotype multiple-testing only (i.e. for each phenotype correcting for the number of tests conducted).</p>
</sec></sec>
</sec>
<sec id="section17-1352458512454345" sec-type="results">
<title>Results</title>
<sec id="section18-1352458512454345">
<title>Patient and imaging descriptives</title>
<p>A total of 326 patients were included for final analysis (262 RRMS and 64 SPMS patients). The mean age of the included patients was 45 years (minimum (min) 19 years, maximum (max) 67 years) with a mean disease duration of 12.3 years (min 0, max 47 years). The median EDSS score was 3 (min 0, max 7.5). Mean NBV was 1548 ml (standard deviation (SD) 88), mean NGMV was 771 ml (SD 68) and mean NWMV was 778 mL (SD 56). Lesion volume measurements showed a mean T2LL-baseline of 6.35 ml (SD 8.40), a mean T1LL-baseline of 2.12 ml (SD 3.36 ml) and a mean T1/T2 ratio of 0.28 (SD 0.18). After one year, the mean T2LL-change was 0.259 ml (SD 1.09) and mean T1LL-change was 0.024 ml (SD 0.459). The PBVC (one year interval) was -0.56% (SD 0.87). (<xref ref-type="table" rid="table1-1352458512454345">Table 1</xref> and Supplementary Figure 1(b)).</p>
<table-wrap id="table1-1352458512454345" position="float">
<label>Table 1.</label>
<caption><p>Demographic details of included subjects.</p></caption>
<graphic alternate-form-of="table1-1352458512454345" xlink:href="10.1177_1352458512454345-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Patient characteristics</th>
<th/>
<th align="left">Number of patients</th>
<th align="left">Mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease type</td>
<td>RRMS</td>
<td>262</td>
<td/>
</tr>
<tr>
<td/>
<td>SPMS</td>
<td>64</td>
<td/>
</tr>
<tr>
<td>Gender</td>
<td>Male</td>
<td>98</td>
<td/>
</tr>
<tr>
<td/>
<td>Female</td>
<td>228</td>
<td/>
</tr>
<tr>
<td>Site</td>
<td>Basel</td>
<td>187</td>
<td/>
</tr>
<tr>
<td/>
<td>Amsterdam</td>
<td>139</td>
<td/>
</tr>
<tr>
<td>Age at time of analysis, mean (range)</td>
<td/>
<td>326</td>
<td>45 (19–67)</td>
</tr>
<tr>
<td>Disease duration in years, mean (range)</td>
<td/>
<td>326</td>
<td>12 (0–47)</td>
</tr>
<tr>
<td>EDSS score, median (range)</td>
<td/>
<td>326</td>
<td>3 (0–7.5)</td>
</tr>
<tr>
<td>NBV, mean (SD), ml</td>
<td/>
<td>326</td>
<td>1548 (88)</td>
</tr>
<tr>
<td>NGMV, mean (SD), ml</td>
<td/>
<td>326</td>
<td>771 (68)</td>
</tr>
<tr>
<td>NWMV, mean (SD), ml</td>
<td/>
<td>326</td>
<td>777 (56)</td>
</tr>
<tr>
<td>T1LL-baseline, mean (SD), ml</td>
<td/>
<td>326</td>
<td>2.12 (3.36)</td>
</tr>
<tr>
<td>T2LL-baseline, mean (SD), ml</td>
<td/>
<td>326</td>
<td>6.35 (8.40)</td>
</tr>
<tr>
<td>T1/T2 ratio, mean (SD)</td>
<td/>
<td>326</td>
<td>0.28 (0.18)</td>
</tr>
<tr>
<td>T1LL-change, mean (SD), ml</td>
<td/>
<td>326</td>
<td>0.024 (0.459)</td>
</tr>
<tr>
<td>T2LL-change, mean (SD), ml</td>
<td/>
<td>326</td>
<td>0.259 (1.094)</td>
</tr>
<tr>
<td>PBVC, mean (SD), %</td>
<td/>
<td>326</td>
<td>–0.56 (0.87)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1352458512454345">
<p>SD: standard deviation; RRMS: relapsing–remitting multiple sclerosis; SPMS: secondary-progressive multiple sclerosis; EDSS: Expanded Disability Status Scale; NBV: normalized brain volume; NGMV: normalized grey matter volume; NWMV: normalized white matter volume; T1LL-baseline: T1-lesion load at baseline; T2LL-baseline: T2-lesion load at baseline; T1/T2-ratio; the ratio beween corresponding T1-lesion load and T2-lesion load at baseline; T1LLchange:T1 lesion load change between year 1 and baseline;T2LL-change: T2 lesion load change between year 1 and baseline; PBVC: percentage brain volume change between year 1 and baseline.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section19-1352458512454345">
<title>Glutamatergic SNPs and phenotypic variability; sRRR results</title>
<p>The sRRR model identified six NMDA-receptor-subunit 2A (GRIN2A) SNPs in rank 1 having a selection probability ≥ 0.50 (shown in <xref ref-type="table" rid="table2-1352458512454345">Table 2</xref>). The top GRIN2A SNP in rank 1 was rs3859123, which was selected with a probability of 0.64 See also <xref ref-type="fig" rid="fig1-1352458512454345">figure 1</xref>. In addition, 14 SNPs related to glutamate signalling genes (GRIN2A (five SNPs), metabotropic glutamate receptor (GRM) 7 (seven SNPs), GRM1 (one SNP) and kainate receptor 4 (GRIK4, one SNP)) were associated with NBV, NGMV and NWMV. The corresponding phenotypes were selected with probabilities 0.815, 0.757 and 0.736, respectively (<xref ref-type="table" rid="table3-1352458512454345">Table 3</xref>). HLA-DRB1*1501 tagging SNP rs3135388 showed no relevant association with any of the phenotypes. This SNP was ranked 3516th in sRRR rank 1.</p>
<table-wrap id="table2-1352458512454345" position="float">
<label>Table 2.</label>
<caption>
<p>Sparse reduced-rank regression (sRRR) genotype selection probabilities.</p>
</caption>
<graphic alternate-form-of="table2-1352458512454345" xlink:href="10.1177_1352458512454345-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">SNP</th>
<th align="left">Selection probability</th>
<th align="center" colspan="4">sRRR genotype selection<hr/></th>
</tr>
<tr>
<th/>
<th/>
<th align="left">Gene</th>
<th align="left">Chr</th>
<th align="left">MAF</th>
<th align="left">HWE <italic>p</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs3859123</td>
<td>0.64</td>
<td>GRIN2A</td>
<td>16</td>
<td>0.316</td>
<td>1</td>
</tr>
<tr>
<td>rs9927924</td>
<td>0.558</td>
<td>GRIN2A</td>
<td>16</td>
<td>0.362</td>
<td>0.4034</td>
</tr>
<tr>
<td>rs6497658</td>
<td>0.522</td>
<td>GRIN2A</td>
<td>16</td>
<td>0.4202</td>
<td>0.9099</td>
</tr>
<tr>
<td>rs13338243</td>
<td>0.505</td>
<td>GRIN2A</td>
<td>16</td>
<td>0.4356</td>
<td>0.9104</td>
</tr>
<tr>
<td>rs1070484</td>
<td>0.5</td>
<td>GRIN2A</td>
<td>16</td>
<td>0.3144</td>
<td>0.3063</td>
</tr>
<tr>
<td>rs3104703</td>
<td>0.5</td>
<td>GRIN2A</td>
<td>16</td>
<td>0.4985</td>
<td>0.03509</td>
</tr>
<tr>
<td>rs10775270</td>
<td>0.488</td>
<td>GRIN2A</td>
<td>16</td>
<td>0.3252</td>
<td>0.449</td>
</tr>
<tr>
<td>rs17824908</td>
<td>0.47</td>
<td>GRM7</td>
<td>3</td>
<td>0.2469</td>
<td>0.7658</td>
</tr>
<tr>
<td>rs11131063</td>
<td>0.468</td>
<td>GRM7</td>
<td>3</td>
<td>0.2485</td>
<td>0.7681</td>
</tr>
<tr>
<td>rs6497676</td>
<td>0.443</td>
<td>GRIN2A</td>
<td>16</td>
<td>0.3252</td>
<td>0.449</td>
</tr>
<tr>
<td>rs10872587</td>
<td>0.43</td>
<td>GRM1</td>
<td>6</td>
<td>0.3313</td>
<td>0.453</td>
</tr>
<tr>
<td>rs2156633</td>
<td>0.422</td>
<td>GRIK4</td>
<td>11</td>
<td>0.2837</td>
<td>0.588</td>
</tr>
<tr>
<td>rs1353828</td>
<td>0.42</td>
<td>GRM7</td>
<td>3</td>
<td>0.2515</td>
<td>1</td>
</tr>
<tr>
<td>rs9880404</td>
<td>0.42</td>
<td>GRM7</td>
<td>3</td>
<td>0.25</td>
<td>0.8826</td>
</tr>
<tr>
<td>rs837688</td>
<td>0.416</td>
<td>GRIN2A</td>
<td>16</td>
<td>0.3865</td>
<td>0.2952</td>
</tr>
<tr>
<td>rs12922641</td>
<td>0.41</td>
<td>GRIN2A</td>
<td>16</td>
<td>0.3451</td>
<td>0.5411</td>
</tr>
<tr>
<td>rs7205180</td>
<td>0.41</td>
<td>GRIN2A</td>
<td>16</td>
<td>0.4877</td>
<td>0.1204</td>
</tr>
<tr>
<td>rs1318267</td>
<td>0.405</td>
<td>GRM7</td>
<td>3</td>
<td>0.2025</td>
<td>0.08504</td>
</tr>
<tr>
<td>rs339804</td>
<td>0.398</td>
<td>GRM7</td>
<td>3</td>
<td>0.3589</td>
<td>0.5473</td>
</tr>
<tr>
<td>rs414907</td>
<td>0.398</td>
<td>GRM7</td>
<td>3</td>
<td>0.3589</td>
<td>0.2785</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1352458512454345">
<p>Single nucleotide polymorphisms (SNPs) selected in the first (top 20 shown) rank of the sRRR model. HWE: Hardy–Weinberg equilibrium; MAF: minor allele frequency. CHR: chromosome. Gene names are listed in supplementary table 1.</p></fn>
</table-wrap-foot>
</table-wrap>
<fig id="fig1-1352458512454345" position="float">
<label>Figure 1.</label>
<caption>
<p>Associations of normalized brain volume (NBV, in litres) and normalized white matter volume (NWMV, in litres) with genetic variability in the GRIN2A SNP, rs3859123. The x-axis displays the three different genotype groups, demonstrating that the GG genotype is associated with reduced NBV (<italic>p</italic> = 0.000306) and NWMV (<italic>p</italic> = 0.001239) relative to the AA genotype group.</p>
</caption>
<graphic xlink:href="10.1177_1352458512454345-fig1.tif"/>
</fig>
<table-wrap id="table3-1352458512454345" position="float">
<label>Table 3.</label>
<caption>
<p>Sparse reduced-rank regression (sRRR) selection probabilities for all phenotypes.</p>
</caption>
<graphic alternate-form-of="table3-1352458512454345" xlink:href="10.1177_1352458512454345-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Phenotype selection</th>
<th align="left">Selection probability</th>
</tr>
</thead>
<tbody>
<tr>
<td>NBV</td>
<td>0.815</td>
</tr>
<tr>
<td>NGMV</td>
<td>0.757</td>
</tr>
<tr>
<td>NWMV</td>
<td>0.736</td>
</tr>
<tr>
<td>T2LL-change</td>
<td>0.618</td>
</tr>
<tr>
<td>T1/T2 ratio</td>
<td>0.603</td>
</tr>
<tr>
<td>PBVC</td>
<td>0.542</td>
</tr>
<tr>
<td>T1LL-change</td>
<td>0.53</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1352458512454345">
<p>Selection probabilities for all phenotypes in sRRR rank 1. NBV: normalized brain volume; NGMV: normalized grey matter volume; NWMV: normalized white matter volume; T1/T2-ratio: the ratio between corresponding T1-lesion load and T2-lesion load; T1LL-change: T1 lesion load change between year 1 and baseline; T2LL-change: T2 lesion load change between year 1 and baseline; PBVC: percentage brain volume change between year 1 and baseline.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>In sRRR rank 2, none of the SNPs had a selection probability ≥ 0.50. Four SNPs (two AMPA receptor 4 (GRIA4) and two NMDA receptor subunit 2B (GRIN2B) gene related SNPs) from the glutamatergic gene group scored highest with selection probabilities 0.439, 0.436, 0.427 and 0.397, respectively. Again, NBV, NGMV and NWMV were the phenotypes that were selected with the highest selection probabilities (0.858, 0.846 and 0.669, respectively) for this rank. Subsequent ranks were not examined as the selection probabilities from the rank 2 analysis were relatively low.</p>
</sec>
<sec id="section20-1352458512454345">
<title>Lasso regression and MULM results</title>
<p>The top sRRR rank 1 SNP rs3859123, a GRIN2A SNP, was selected by both Lasso regression and MULM in association with NBV and NWMV (<xref ref-type="table" rid="table4-1352458512454345">Table 4</xref> and Supplementary Table 2). Furthermore, eight other GRIN2A SNPs showed an association with either NBV or NWMV when using Lasso and MULM.</p>
<table-wrap id="table4-1352458512454345" position="float">
<label>Table 4.</label>
<caption>
<p>Lasso and mass-univariate linear modelling (MULM) results for the six single nucleotide polymorphisms (SNPs) selected by sparse reduced-rank regression (sRRR) with selection probability ≥ 0.5.</p>
</caption>
<graphic alternate-form-of="table4-1352458512454345" xlink:href="10.1177_1352458512454345-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="center" colspan="3">sRRR genotype selection<hr/></th>
<th align="center" colspan="3">Lasso<hr/></th>
<th align="center" colspan="3">MULM<hr/></th>
</tr>
<tr>
<th align="left">SNP</th>
<th align="left">Selection probability</th>
<th align="left">Gene</th>
<th align="left">Phenotype</th>
<th align="left">Selection probability</th>
<th align="left">Place</th>
<th align="left">Phenotype</th>
<th align="left"><italic>p</italic>-value</th>
<th align="left">Place</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs3859123</td>
<td>0.64</td>
<td>GRIN2A</td>
<td>NBV</td>
<td>0.581</td>
<td>2nd</td>
<td>NBV</td>
<td>0.000306</td>
<td>1st</td>
</tr>
<tr>
<td>rs9927924</td>
<td>0.558</td>
<td>GRIN2A</td>
<td>NWMV</td>
<td>0.352</td>
<td>11th</td>
<td>NWMV</td>
<td>0.000393</td>
<td>1st</td>
</tr>
<tr>
<td>rs6497658</td>
<td>0.522</td>
<td>GRIN2A</td>
<td>NBV</td>
<td>0.262</td>
<td>30th</td>
<td>NWMV</td>
<td>0.002482</td>
<td>6th</td>
</tr>
<tr>
<td>rs13338243</td>
<td>0.505</td>
<td>GRIN2A</td>
<td>NBV</td>
<td>0.134</td>
<td>163rd</td>
<td>NBV</td>
<td>0.009192</td>
<td>11th</td>
</tr>
<tr>
<td>rs1070484</td>
<td>0.5</td>
<td>GRIN2A</td>
<td>NWMV</td>
<td>0.077</td>
<td>702nd</td>
<td>NWMV</td>
<td>0.002631</td>
<td>9th</td>
</tr>
<tr>
<td>rs3104703</td>
<td>0.5</td>
<td>GRIN2A</td>
<td>NBV</td>
<td>0.338</td>
<td>15th</td>
<td>NBV</td>
<td>0.001342</td>
<td>2nd</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-1352458512454345"><p>Lasso and MULM associations (selection probability and <italic>p</italic>-value resp.) for the six SNPs selected by sRRR with selection probability ≥ 0.5. <italic>p</italic>-value: <italic>p</italic>-value of SNP-phenotype association.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Four GRM5 SNPs showed significant associations with T2LL-change using MULM (top SNP rs7483764, lowest <italic>p</italic>-value 2.33*10<sup>-5</sup>, which remained significant after per-phenotype Bonferroni-correction) and Lasso regression (selection probability 0.511). This SNP scored 32nd in sRRR rank 1 (selection probability 0.36). Concerning the HLA-DRB1*1501 susceptibility SNP rs3135388, Lasso analysis showed a selection probability in association with T2LL-change of 0.105 (placed 495th in the complete Lasso analysis with T2LL-change) and for the MULM a <italic>p</italic>-value of 0.19 (placed 707th in the complete MULM analysis with T2LL-change).</p>
</sec></sec>
<sec id="section21-1352458512454345" sec-type="discussion">
<title>Discussion</title>
<p>In this study, we used three different regression models on a well-characterized clinical and MR-imaging dataset of 326 MS patients from two European MS referral centres. Two penalized regression models, the multivariate sRRR model and the univariate-phenotype Lasso model, as well as the more conventional MULM were used to study the effects of genetic variation in 33 genes involved in brain glutamate metabolism on seven different MRI phenotypes in MS. The results across all three analyses showed consistent associations of ionotropic glutamate receptor GRIN2A SNPs with NBV and NWMV.</p>
<p>MS susceptibility and disease expression are believed to be the result of a complex interplay of environmental, genetic and even epigenetic factors,<sup><xref ref-type="bibr" rid="bibr21-1352458512454345">21</xref><xref ref-type="bibr" rid="bibr22-1352458512454345"/>-<xref ref-type="bibr" rid="bibr23-1352458512454345">23</xref></sup> which eventually lead to a heterogeneous phenotypic expression that can be captured in detail by neuroimaging studies.<sup><xref ref-type="bibr" rid="bibr24-1352458512454345">24</xref><xref ref-type="bibr" rid="bibr25-1352458512454345"/>–<xref ref-type="bibr" rid="bibr26-1352458512454345">26</xref></sup> After successful genetic susceptibility studies in recent years, previous studies using MRI and genetics data to study genotype–phenotype associations have resulted in a number of only modest relations. First, candidate gene studies have generated associations of individual SNPs with a variety of individual MRI phenotypes.<sup><xref ref-type="bibr" rid="bibr27-1352458512454345">27</xref>,<xref ref-type="bibr" rid="bibr28-1352458512454345">28</xref></sup> Secondly, genome-wide association studies (GWASs) showed that several glutamatergic SNPs were moderately associated with higher T2-lesion loads, lower NBV and abnormal MR-spectroscopy findings on glutamate metabolism. Also, a pathway-based analysis of GWAS data identified a biological module consisting of several glutamate related SNPs that jointly were associated with increased susceptibility.<sup><xref ref-type="bibr" rid="bibr10-1352458512454345">10</xref>,<xref ref-type="bibr" rid="bibr29-1352458512454345">29</xref></sup> Taken together, in contrast to diseases such as Alzheimer’s disease where the major susceptibility gene ApoE is also associated with a more severe disease course,<sup><xref ref-type="bibr" rid="bibr30-1352458512454345">30</xref></sup> a similar general disease modifying effect of susceptibility genes does not seem to be present in MS.<sup><xref ref-type="bibr" rid="bibr31-1352458512454345">31</xref></sup> Other genetic variants than those found in susceptibility studies may thus influence phenotypic variation in this disease.</p>
<p>When determining the extent to which genetic variation contributes to phenotypic variability, a number of statistical challenges have to be overcome. The most common genotype–phenotype association approach involves the fitting of a massive number of linear models, regressing each phenotype onto each genetic variant one at a time, performing hypothesis testing and then ultimately correcting for multiple testing. This MULM approach becomes extremely challenging with increasing numbers of genetic variants tested and with higher dimensionality of imaging-phenotypes used as readouts.<sup><xref ref-type="bibr" rid="bibr4-1352458512454345">4</xref></sup> An additional disadvantage of the traditional univariate linear modelling approach is that it treats each marker independently and is as such unable to capture possible cumulative effects from multiple genetic markers. Furthermore, it does not allow for a combination of predicted phenotypes, which is a crucial step when attempting to explain phenotype heterogeneity in a highly complex disease like MS.</p>
<p>Advanced statistical models like the sRRR model hold promise for overcoming these difficulties because they can detect genotype–phenotype associations with greater power by capturing possible cumulative effects.<sup><xref ref-type="bibr" rid="bibr5-1352458512454345">5</xref>,<xref ref-type="bibr" rid="bibr6-1352458512454345">6</xref></sup> As reported previously, the sRRR approach performs both genotype and phenotype selection and offers a way of simultaneously searching for multiple markers that are highly predictive of a combination of phenotypes. Hence, the sRRR approach also accounts for the multivariate nature of disease expression and has the potential to amplify the signal and eventually increase the power to detect true associations.</p>
<p>With this study, we provide new evidence that genetic variants of glutamate metabolism are associated with altered expression of neurodegenerative phenotypes in a large, multicentre MS cohort. Glutamate, the major excitatory neurotransmitter in the CNS, has been implicated in both neurodegeneration and neuroinflammation in a variety of neurological disorders including MS. Glutamate signalling involves activation of ionotropic (iGluRs, voltage-gated channels including NMDA, alpha-amino-3- hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate receptors) and metabotropic glutamate receptors (mGluRs, G-protein coupled receptors) which are expressed on neurons and glial cells throughout the CNS. Under normal conditions a tightly controlled cerebral glutamate concentration is provided but increased glutamate concentrations are seen in various pathological conditions, and can ultimately lead to excitotoxic neuronal and glial cell death and neurodegeneration.<sup><xref ref-type="bibr" rid="bibr32-1352458512454345">32</xref><xref ref-type="bibr" rid="bibr33-1352458512454345"/>–<xref ref-type="bibr" rid="bibr34-1352458512454345">34</xref></sup></p>
<p>Increased concentrations of glutamate in the cerebrospinal fluid of MS patients have been associated with the severity and course of the disease.<sup><xref ref-type="bibr" rid="bibr35-1352458512454345">35</xref></sup> Supporting this, in vivo spectroscopy studies have shown alterations in glutamate metabolism in acute MS lesions and normal appearing white matter.<sup><xref ref-type="bibr" rid="bibr36-1352458512454345">36</xref></sup> In addition, post mortem studies have shown altered glutamate transporter expression in MS brain tissue,<sup><xref ref-type="bibr" rid="bibr37-1352458512454345">37</xref></sup> altered expression of mGluRs<sup><xref ref-type="bibr" rid="bibr10-1352458512454345">10</xref>,<xref ref-type="bibr" rid="bibr11-1352458512454345">11</xref></sup> and altered expression of glutamate metabolizing enzymes,<sup><xref ref-type="bibr" rid="bibr38-1352458512454345">38</xref></sup> which implies an important role of the complete group of glutamate-related proteins. Furthermore, glutamate transporter polymorphisms have been found to affect the glutamate concentration in MS brain tissue<sup><xref ref-type="bibr" rid="bibr10-1352458512454345">10</xref>,<xref ref-type="bibr" rid="bibr38-1352458512454345">38</xref></sup> suggesting that genetic variants of glutamate-related proteins can modulate glutamate homeostasis. In the present study, we found consistent evidence that variants of GRIN2A (the gene that codes for the NMDA receptor (NMDAR) subunit 2A) were consistently associated with NBV and NWMV. NMDARs are expressed on neurons, astrocytes, oligodendrocyte processes and on the compact myelin that ensheaths axons in the cerebral white matter. When excessively stimulated or activated, NMDARs increase intracellular Ca<sup>2+</sup> and as such are a major contributor to neuronal and oligodendrocyte death.<sup><xref ref-type="bibr" rid="bibr39-1352458512454345">39</xref><xref ref-type="bibr" rid="bibr40-1352458512454345"/><xref ref-type="bibr" rid="bibr41-1352458512454345"/><xref ref-type="bibr" rid="bibr42-1352458512454345"/><xref ref-type="bibr" rid="bibr43-1352458512454345"/>–<xref ref-type="bibr" rid="bibr44-1352458512454345">44</xref></sup> The top five associated GRIN2A SNPs in this study are all localized in intron regions and currently have no known functional effect. However, the effects of micro-RNAs (primarily located in intron regions of host genes) are becoming better understood<sup><xref ref-type="bibr" rid="bibr45-1352458512454345">45</xref></sup> and although not ‘functional’ on a level of qualitatively altered transcripts of GRIN2A, the found SNPs might exert effects on more quantitatively altered transcripts (i.e. increased or decreased transcription of GRIN2A).</p>
<p>Despite the novelty and interest of these results, caution is needed when applying a new statistical model like sRRR. Although validated after extensive simulations<sup><xref ref-type="bibr" rid="bibr9-1352458512454345">9</xref></sup> and applied to a comprehensive genotype-phenotype dataset<sup><xref ref-type="bibr" rid="bibr30-1352458512454345">30</xref></sup>, this is the first time that sRRR has been applied to an MS dataset. Therefore, the sRRR results cannot be compared with previous results from previous studies that used different statistical models. In the present study we further applied two individual-phenotype analysis models, MULM and Lasso regression. This application of different statistical models allowed us to evaluate the consistency of findings across the models and detect the SNPs with the strongest effects on the imaging-phenotypes. Regarding the functional relevance of the observed associations, the absence of a healthy age- and sex-matched control group prevented us from concluding that the found genotype–phenotype associations are unique to MS. It could well be that the observed associations with brain volume measures can be found in different neurodegenerative diseases and also with ageing.</p>
<p>A primary interest of our study is in its application of a novel statistical method, which overcomes important statistical problems that have been a major point of difficulty in previous genetic association studies. After subsequent application of two different, independent, statistical methods, we showed consistency of our findings across these independent models. Furthermore, this simultaneous analysis of multiple phenotypes in this heterogeneous disease like MS allows us for the first time to better understand the interplay between genetic variants and disease expression amongst multiple MRI-derived phenotypes. Despite the limitations of this exploratory study, the novel statistical method has provided plausible new genotype–phenotype associations for further exploration. Following on the successes of genetic association studies for susceptibility to MS, further studies are needed to identify genetic factors driving phenotypic expression of MS to develop tools to assist in better understanding the prognosis of individual patients.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p></fn>
<fn fn-type="conflict">
<label>Conflict of interest statement</label>
<p>The authors declare no conflicts of interest in preparing this article.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1352458512454345">
<label>1.</label>
<citation citation-type="journal">
<collab>IMSGC; WTCCC2</collab>, <person-group person-group-type="author">
<name><surname>Sawcer</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Genetic risk and a primary role for cell-mediate immune mechanisms in multiple sclerosis</article-title>. <source>Nature</source> <year>2011</year>; <volume>476</volume>: <fpage>214</fpage>–<lpage>219</lpage>.</citation>
</ref> <ref id="bibr2-1352458512454345">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Jager</surname><given-names>PL</given-names></name>
<name><surname>Jia</surname><given-names>X</given-names></name>
<name><surname>Wang</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci</article-title>. <source>Nat Genet</source> <year>2009</year>; <volume>41</volume>: <fpage>776</fpage>–<lpage>782</lpage>.</citation>
</ref>
<ref id="bibr3-1352458512454345">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baranzini</surname><given-names>SE</given-names></name>
<name><surname>Wang</surname><given-names>J</given-names></name>
<name><surname>Gibson</surname><given-names>RA</given-names></name>
<etal/>
</person-group>. <article-title>Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis</article-title>. <source>Hum Mol Genet</source> <year>2009</year>; <volume>18</volume>: <fpage>767</fpage>–<lpage>778</lpage>.</citation>
</ref> <ref id="bibr4-1352458512454345">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sawcer</surname><given-names>S</given-names></name>
</person-group>. <article-title>The complex genetics of multiple sclerosis: Pitfalls and prospects</article-title>. <source>Brain</source> <year>2008</year>; <volume>131</volume>: <fpage>3118</fpage>–<lpage>3131</lpage>.</citation>
</ref>
<ref id="bibr5-1352458512454345">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ayers</surname><given-names>KL</given-names></name>
<name><surname>Cordell</surname><given-names>HJ</given-names></name>
</person-group>. <article-title>SNP selection in genome-wide and candidate gene studies via penalized logistic regression</article-title>. <source>Genet Epidemiol</source> <year>2010</year>; <volume>34</volume>: <fpage>879</fpage>–<lpage>891</lpage>.</citation>
</ref>
<ref id="bibr6-1352458512454345">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shi</surname><given-names>G</given-names></name>
<name><surname>Boerwinkle</surname><given-names>E</given-names></name>
<name><surname>Morrison</surname><given-names>AC</given-names></name>
<etal/>
</person-group>. <article-title>Mining gold dust under the genome wide significance level: A two-stage approach to analysis of GWAS</article-title>. <source>Genet Epidemiol</source> <year>2011</year>; <volume>35</volume>: <fpage>111</fpage>–<lpage>118</lpage>.</citation>
</ref> <ref id="bibr7-1352458512454345">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vounou</surname><given-names>M</given-names></name>
<name><surname>Nichols</surname><given-names>TE</given-names></name>
<name><surname>Montana</surname><given-names>G</given-names></name>
</person-group>. <article-title>Discovering genetic associations with high-dimensional neuroimaging phenotypes: A sparse reduced-rank regression approach</article-title>. <source>Neuroimage</source> <year>2010</year>; <volume>53</volume>: <fpage>1147</fpage>–<lpage>1159</lpage>.</citation>
</ref>
<ref id="bibr8-1352458512454345">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Geurts</surname><given-names>JJ</given-names></name>
<name><surname>Wolswijk</surname><given-names>G</given-names></name>
<name><surname>Bo</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis</article-title>. <source>Brain</source> <year>2003</year>; <volume>126</volume>: <fpage>1755</fpage>–<lpage>1766</lpage>.</citation>
</ref>
<ref id="bibr9-1352458512454345">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Geurts</surname><given-names>JJ</given-names></name>
<name><surname>Wolswijk</surname><given-names>G</given-names></name>
<name><surname>Bo</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Expression patterns of Group III metabotropic glutamate receptors mGluR4 and mGluR8 in multiple sclerosis lesions</article-title>. <source>J Neuroimmunol</source> <year>2005</year>; <volume>158</volume>: <fpage>182</fpage>–<lpage>190</lpage>.</citation>
</ref>
<ref id="bibr10-1352458512454345">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baranzini</surname><given-names>SE</given-names></name>
<name><surname>Srinivasan</surname><given-names>R</given-names></name>
<name><surname>Khankhanian</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Genetic variation influences glutamate concentrations in brains of patients with multiple sclerosis</article-title>. <source>Brain</source> <year>2010</year>; <volume>133</volume>: <fpage>2603</fpage>–<lpage>2611</lpage>.</citation>
</ref>
<ref id="bibr11-1352458512454345">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Polman</surname><given-names>CH</given-names></name>
<name><surname>Reingold</surname><given-names>SC</given-names></name>
<name><surname>Edan</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald Criteria’</article-title>. <source>Ann Neurol</source> <year>2005</year>; <volume>58</volume>: <fpage>840</fpage>–<lpage>846</lpage>.</citation>
</ref>
<ref id="bibr12-1352458512454345">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kurtzke</surname><given-names>JF</given-names></name>
</person-group>. <article-title>Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)</article-title>. <source>Neurology</source> <year>1983</year>; <volume>33</volume>: <fpage>1444</fpage>–<lpage>1452</lpage>.</citation>
</ref>
<ref id="bibr13-1352458512454345">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smith</surname><given-names>SM</given-names></name>
<name><surname>Zhang</surname><given-names>Y</given-names></name>
<name><surname>Jenkinson</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Accurate, robust, and automated longitudinal and cross-sectional brain change analysis</article-title>. <source>Neuroimage</source> <year>2002</year>; <volume>17</volume>: <fpage>479</fpage>–<lpage>489</lpage>.</citation>
</ref>
<ref id="bibr14-1352458512454345">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Purcell</surname><given-names>S</given-names></name>
<name><surname>Neale</surname><given-names>B</given-names></name>
<name><surname>Todd-Brown</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>PLINK: A tool set for whole-genome association and population-based linkage analyses</article-title>. <source>Am J Hum Genet</source> <year>2007</year>; <volume>81</volume>: <fpage>559</fpage>–<lpage>575</lpage>.</citation>
</ref>
<ref id="bibr15-1352458512454345">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Okuda</surname><given-names>DT</given-names></name>
<name><surname>Srinivasan</surname><given-names>R</given-names></name>
<name><surname>Oksenberg</surname><given-names>JR</given-names></name>
<etal/>
</person-group>. <article-title>Genotype– phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures</article-title>. <source>Brain</source> <year>2009</year>; <volume>132</volume>: <fpage>250</fpage>–<lpage>259</lpage>.</citation>
</ref>
<ref id="bibr16-1352458512454345">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Benjamini</surname><given-names>Y</given-names></name>
<name><surname>Hochberg</surname><given-names>Y</given-names></name>
</person-group>. <article-title>Controlling the false discovery rate: A practical and powerful approach to multiple testing</article-title>. <source>J Royal Statist Soc B</source> <year>1995</year>; <volume>57</volume>: <fpage>289</fpage>–<lpage>300</lpage>.</citation>
</ref>
<ref id="bibr17-1352458512454345">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Benjamini</surname><given-names>Y</given-names></name>
<name><surname>Yekutieli</surname><given-names>D</given-names></name>
</person-group>. <article-title>The control of the false discovery rate in multiple testing under dependency</article-title>. <source>Ann Statist</source> <year>2001</year>; <volume>29</volume>: <fpage>1165</fpage>–<lpage>1188</lpage>.</citation>
</ref>
<ref id="bibr18-1352458512454345">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Breiman</surname><given-names>L</given-names></name>
</person-group>. <article-title>Stacked regressions</article-title>. <source>Machine Learn</source> <year>1996</year>; <volume>24</volume>: <fpage>49</fpage>–<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr19-1352458512454345">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Breiman</surname><given-names>L</given-names></name>
<name><surname>Friedman</surname><given-names>J</given-names></name>
</person-group>. <article-title>Predicting multivariate responses in multiple linear regression</article-title>. <source>J Royal Statist Soc B (Methodological)</source> <year>1997</year>; <volume>59</volume>: <fpage>3</fpage>–<lpage>54</lpage>.</citation>
</ref>
<ref id="bibr20-1352458512454345">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tibshirani</surname><given-names>R</given-names></name>
</person-group>. <article-title>Regression shrinkage and selection via the Lasso</article-title>. <source>J Royal Statist Soc B</source> <year>1996</year>; <volume>58</volume>: <fpage>267</fpage>–<lpage>288</lpage>.</citation>
</ref>
<ref id="bibr21-1352458512454345">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Urdinguio</surname><given-names>RG</given-names></name>
<name><surname>Sanchez-Mut</surname><given-names>JV</given-names></name>
<name><surname>Esteller</surname><given-names>M</given-names></name>
</person-group>. <article-title>Epigenetic mechanisms in neurological diseases: Genes, syndromes, and therapies</article-title>. <source>Lancet Neurol</source> <year>2009</year>; <volume>8</volume>: <fpage>1056</fpage>–<lpage>1072</lpage>.</citation>
</ref>
<ref id="bibr22-1352458512454345">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Handunnetthi</surname><given-names>L</given-names></name>
<name><surname>Ramagopalan</surname><given-names>SV</given-names></name>
<name><surname>Ebers</surname><given-names>GC</given-names></name>
</person-group>. <article-title>Multiple sclerosis, vitamin D, and HLA-DRB1*15</article-title>. <source>Neurology</source> <year>2010</year>; <volume>74</volume>: <fpage>1905</fpage>–<lpage>1910</lpage>.</citation>
</ref>
<ref id="bibr23-1352458512454345">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Jager</surname><given-names>PL</given-names></name>
<name><surname>Chibnik</surname><given-names>LB</given-names></name>
<name><surname>Cui</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: A weighted genetic risk score</article-title>. <source>Lancet Neurol</source> <year>2009</year>; <volume>8</volume>: <fpage>1111</fpage>–<lpage>1119</lpage>.</citation>
</ref>
<ref id="bibr24-1352458512454345">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van Walderveen</surname><given-names>MA</given-names></name>
<name><surname>Lycklama</surname><given-names>ANG</given-names></name>
<name><surname>Ader</surname><given-names>HJ</given-names></name>
<etal/>
</person-group>. <article-title>Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: Relation to clinical characteristics in subgroups of patients with multiple sclerosis</article-title>. <source>Arch Neurol</source> <year>2001</year>; <volume>58</volume>: <fpage>76</fpage>–<lpage>81</lpage>.</citation>
</ref>
<ref id="bibr25-1352458512454345">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barkhof</surname><given-names>F</given-names></name>
<name><surname>Bruck</surname><given-names>W</given-names></name>
<name><surname>de Groot</surname><given-names>CJ</given-names></name>
<etal/>
</person-group>. <article-title>Remyelinated lesions in multiple sclerosis: Magnetic resonance image appearance</article-title>. <source>Arch Neurol</source> <year>2003</year>; <volume>60</volume>: <fpage>1073</fpage>–<lpage>1081</lpage>.</citation>
</ref>
<ref id="bibr26-1352458512454345">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fisher</surname><given-names>E</given-names></name>
<name><surname>Lee</surname><given-names>JC</given-names></name>
<name><surname>Nakamura</surname><given-names>K</given-names></name>
<name><surname>Rudick</surname><given-names>RA</given-names></name>
</person-group>. <article-title>Gray matter atrophy in multiple sclerosis: A longitudinal study</article-title>. <source>Ann Neurol</source> <year>2008</year>; <volume>64</volume>: <fpage>255</fpage>–<lpage>265</lpage>.</citation>
</ref>
<ref id="bibr27-1352458512454345">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zivadinov</surname><given-names>R</given-names></name>
<name><surname>Uxa</surname><given-names>L</given-names></name>
<name><surname>Bratina</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis</article-title>. <source>Int Rev Neurobiol</source> <year>2007</year>; <volume>79</volume>: <fpage>521</fpage>–<lpage>535</lpage>.</citation>
</ref>
<ref id="bibr28-1352458512454345">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sombekke</surname><given-names>MH</given-names></name>
<name><surname>Lukas</surname><given-names>C</given-names></name>
<name><surname>Crusius</surname><given-names>JB</given-names></name>
<etal/>
</person-group>. <article-title>HLA-DRB1*1501 and spinal cord magnetic resonance imaging lesions in multiple sclerosis</article-title>. <source>Arch Neurol</source> <year>2009</year>; <volume>66</volume>: <fpage>1531</fpage>–<lpage>1536</lpage>.</citation>
</ref>
<ref id="bibr29-1352458512454345">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baranzini</surname><given-names>SE</given-names></name>
<name><surname>Galwey</surname><given-names>NW</given-names></name>
<name><surname>Wang</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Pathway and network-based analysis of genome-wide association studies in multiple sclerosis</article-title>. <source>Hum Mol Genet</source> <year>2009</year>; <volume>18</volume>: <fpage>2078</fpage>–<lpage>2090</lpage>.</citation>
</ref>
<ref id="bibr30-1352458512454345">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vounou</surname><given-names>M</given-names></name>
<name><surname>Janousova</surname><given-names>E</given-names></name>
<name><surname>Wolz</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Alzheimer’s Disease Neuroimaging Initiative. Sparse reduced-rank regression detects genetic associations with voxel-wise longitudinal phenotypes in Alzheimer’s disease</article-title>. <source>Neuroimage</source> <year>2012</year>; <volume>60</volume>: <fpage>700</fpage>–<lpage>716</lpage>.</citation>
</ref>
<ref id="bibr31-1352458512454345">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lundström</surname><given-names>W</given-names></name>
<name><surname>Greiner</surname><given-names>E</given-names></name>
<name><surname>Lundmark</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>No influence on disease progression of non-HLA susceptibility genes in MS</article-title>. <source>J Neuroimmunol</source> <year>2011</year>; <volume>237</volume>: <fpage>98</fpage>–<lpage>100</lpage>.</citation>
</ref>
<ref id="bibr32-1352458512454345">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Choi</surname><given-names>DW</given-names></name>
</person-group>. <article-title>Glutamate neurotoxicity and diseases of the nervous system</article-title>. <source>Neuron</source> <year>1988</year>; <volume>1</volume>: <fpage>623</fpage>–<lpage>634</lpage>.</citation>
</ref>
<ref id="bibr33-1352458512454345">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Matute</surname><given-names>C</given-names></name>
<name><surname>Domercq</surname><given-names>M</given-names></name>
<name><surname>Sanchez-Gomez</surname><given-names>MV.</given-names>
</name>
</person-group> <article-title>Glutamate-mediated glial injury: Mechanisms and clinical importance</article-title>. <source>Glia</source> <year>2006</year>; <volume>53</volume>: <fpage>212</fpage>–<lpage>224</lpage>.</citation>
</ref>
<ref id="bibr34-1352458512454345">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Domercq</surname><given-names>M</given-names></name>
<name><surname>Etxebarria</surname><given-names>E</given-names></name>
<name><surname>Perez-Samartin</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Excitotoxic oligodendrocyte death and axonal damage induced by glutamate transporter inhibition</article-title>. <source>Glia</source> <year>2005</year>; <volume>52</volume>: <fpage>36</fpage>–<lpage>46</lpage>.</citation>
</ref>
<ref id="bibr35-1352458512454345">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barkhatova</surname><given-names>VP</given-names></name>
<name><surname>Zavalishin</surname><given-names>IA</given-names></name>
<name><surname>Askarova</surname><given-names>LS</given-names></name>
<etal/>
</person-group>. <article-title>Changes in neurotransmitters in multiple sclerosis</article-title>. <source>Neurosci Behav Physiol</source> <year>1998</year>; <volume>28</volume>: <fpage>341</fpage>–<lpage>344</lpage>.</citation>
</ref>
<ref id="bibr36-1352458512454345">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Srinivasan</surname><given-names>R</given-names></name>
<name><surname>Sailasuta</surname><given-names>N</given-names></name>
<name><surname>Hurd</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T</article-title>. <source>Brain</source> <year>2005</year>; <volume>128</volume>: <fpage>1016</fpage>–<lpage>1025</lpage>.</citation>
</ref>
<ref id="bibr37-1352458512454345">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vallejo-Illarramendi</surname><given-names>A</given-names></name>
<name><surname>Domercq</surname><given-names>M</given-names></name>
<name><surname>Perez-Cerda</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Increased expression and function of glutamate transporters in multiple sclerosis</article-title>. <source>Neurobiol Dis</source> <year>2006</year>; <volume>21</volume>: <fpage>154</fpage>–<lpage>164</lpage>.</citation>
</ref>
<ref id="bibr38-1352458512454345">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pampliega</surname><given-names>O</given-names></name>
<name><surname>Domercq</surname><given-names>M</given-names></name>
<name><surname>Villoslada</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Association of an EAAT2 polymorphism with higher glutamate concentration in relapsing multiple sclerosis</article-title>. <source>J Neuroimmunol</source> <year>2008</year>; <volume>195</volume>: <fpage>194</fpage>–<lpage>198</lpage>.</citation>
</ref>
<ref id="bibr39-1352458512454345">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Werner</surname><given-names>P</given-names></name>
<name><surname>Pitt</surname><given-names>D</given-names></name>
<name><surname>Raine</surname><given-names>CS</given-names></name>
</person-group>. <article-title>Multiple sclerosis: Altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage</article-title>. <source>Ann Neurol</source> <year>2001</year>; <volume>50</volume>: <fpage>169</fpage>–<lpage>180</lpage>.</citation>
</ref>
<ref id="bibr40-1352458512454345">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pina-Crespo</surname><given-names>JC</given-names></name>
<name><surname>Talantova</surname><given-names>M</given-names></name>
<name><surname>Micu</surname><given-names>I</given-names></name>
<etal/>
</person-group>. <article-title>Excitatory glycine responses of CNS myelin mediated by NR1/NR3 ‘NMDA’ receptor subunits</article-title>. <source>J Neurosci</source> <year>2010</year>; <volume>30</volume>: <fpage>11501</fpage>–<lpage>11505</lpage>.</citation>
</ref>
<ref id="bibr41-1352458512454345">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zamponi</surname><given-names>GW</given-names></name>
<name><surname>Stys</surname><given-names>PK</given-names></name>
</person-group>. <article-title>Role of prions in neuroprotection and neurodegeneration: A mechanism involving glutamate receptors?</article-title> <source>Prion</source> <year>2009</year>; <volume>3</volume>: <fpage>187</fpage>–<lpage>189</lpage>.</citation>
</ref>
<ref id="bibr42-1352458512454345">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Micu</surname><given-names>I</given-names></name>
<name><surname>Jiang</surname><given-names>Q</given-names></name>
<name><surname>Coderre</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>NMDA receptors mediate calcium accumulation in myelin during chemical ischaemia</article-title>. <source>Nature</source> <year>2006</year>; <volume>439</volume>: <fpage>988</fpage>–<lpage>992</lpage>.</citation>
</ref>
<ref id="bibr43-1352458512454345">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Trapp</surname><given-names>BD</given-names></name>
<name><surname>Stys</surname><given-names>PK</given-names></name>
</person-group>. <article-title>Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis</article-title>. <source>Lancet Neurol</source> <year>2009</year>; <volume>8</volume>: <fpage>280</fpage>–<lpage>291</lpage>.</citation>
</ref>
<ref id="bibr44-1352458512454345">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Salter</surname><given-names>MG</given-names></name>
<name><surname>Fern</surname><given-names>R</given-names></name>
</person-group>. <article-title>NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury</article-title>. <source>Nature</source> <year>2005</year>; <volume>438</volume>: <fpage>1167</fpage>–<lpage>1171</lpage>.</citation>
</ref>
<ref id="bibr45-1352458512454345">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Salta</surname><given-names>E</given-names></name>
<name><surname>de Strooper</surname><given-names>B</given-names></name>
</person-group>. <article-title>Non-coding RNAs with essential roles in neurodegenerative disorders</article-title>. <source>Lancet Neurol</source> <year>2012</year>; <volume>11</volume>: <fpage>189</fpage>–<lpage>200</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>